Neuraly, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neuraly, Inc.
Can Incretins Treat Parkinson’s Disease?
Only one biopharma group is actively trialing a GLP-1 agonist in the condition. It might not be alone for long.
AbbVie’s Parkinson’s Plans Back In The PINK With Mitokinin Buy
Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.
Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment
The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- D&D Pharmatech
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice